Last reviewed · How we verify
NCT06562270
CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry
trial in Alopecia Areata in 1,500 participants. Currently enrolling.
31 December 2099
Quick facts
| Lead sponsor | CorEvitas |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,500 |
| Start date | 7 March 2024 |
| Primary completion | 31 December 2099 |
| Estimated completion | 31 December 2099 |
| Sites | 1 location across United States |
Conditions studied
- Alopecia Areata — all drugs for Alopecia Areata →
Sponsor
CorEvitas — full company profile →
Who can join
Adults 12 to 17, any sex, with Alopecia Areata. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prospective observational registry focusing on an adolescent cohort diagnosed with severe alopecia areata,receiving routine care from dermatology providers. Visit schedules for patients will be determined by the provider in accordance with routine clinical care, and any prescriptions provided to patients will adhere to product availability and local prescribing guidelines/regulations in the country where the participating registry site is located.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06562270
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alopecia Areata
Currently open trials in the same condition.
- NCT07242638 — Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome · Phase 2 · recruiting
- NCT07311564 — A Study of LAD603 in Adults With Alopecia Areata · Phase 2 · recruiting
- NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting
- NCT07205159 — A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata. · Phase 1 · recruiting
- NCT06747611 — Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata · Phase 2 · recruiting
Other CorEvitas trials
Trials by the same sponsor.
- NCT07420075 — Alzheimer's Registry · enrolling by invitation
- NCT07217509 — PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Effectiveness Registry · enrolling by invitation
- NCT06804057 — CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry · recruiting
- NCT06521944 — RSV Vaccine Pregnancy Registry · recruiting
- NCT06238765 — CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06562270 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CorEvitas
- Last refreshed: 9 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06562270.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing